Cargando…

Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()

Progressive loss of substantia nigra dopamine neurons (SN DA) is a hallmark of aging and of Parkinson's disease (PD). Mutations in PARK genes cause familial PD forms. Increased expression of alpha-synuclein (PARK4) is a disease-triggering event in familial PD and also observed in SN DA neurons...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlaudraff, Falk, Gründemann, Jan, Fauler, Michael, Dragicevic, Elena, Hardy, John, Liss, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099518/
https://www.ncbi.nlm.nih.gov/pubmed/24742361
http://dx.doi.org/10.1016/j.neurobiolaging.2014.03.016
_version_ 1782326497664565248
author Schlaudraff, Falk
Gründemann, Jan
Fauler, Michael
Dragicevic, Elena
Hardy, John
Liss, Birgit
author_facet Schlaudraff, Falk
Gründemann, Jan
Fauler, Michael
Dragicevic, Elena
Hardy, John
Liss, Birgit
author_sort Schlaudraff, Falk
collection PubMed
description Progressive loss of substantia nigra dopamine neurons (SN DA) is a hallmark of aging and of Parkinson's disease (PD). Mutations in PARK genes cause familial PD forms. Increased expression of alpha-synuclein (PARK4) is a disease-triggering event in familial PD and also observed in SN DA neurons in sporadic PD but related transcriptional changes are unknown. With optimized single-cell quantitative real-time polymerase chain reaction analysis, we compared messenger RNA and microRNA levels in SN DA neurons from sporadic PD patients and controls. Non-optimally matched donor ages and RNA integrities are common problems when analyzing human samples. We dissected the influence of distinct ages and RNA integrities of our samples by applying a specifically-optimized, linear-mixed-effects model to quantitative real-time polymerase chain reaction-data. We identified that elevated alpha-synuclein messenger RNA levels in SN DA neurons of human PD brains were positively correlated with corresponding elevated levels of mRNAs for functional compensation of progressive SN DA loss and for enhanced proteasomal (PARK5/UCHL1) and lysosomal (PARK9/ATPase13A2) function, possibly counteracting alpha-synuclein toxicity. In contrast, microRNA miR-133b levels, previously implicated in transcriptional dysregulation in PD, were not altered in SN DA neurons in PD.
format Online
Article
Text
id pubmed-4099518
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-40995182014-10-01 Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease() Schlaudraff, Falk Gründemann, Jan Fauler, Michael Dragicevic, Elena Hardy, John Liss, Birgit Neurobiol Aging Regular Article Progressive loss of substantia nigra dopamine neurons (SN DA) is a hallmark of aging and of Parkinson's disease (PD). Mutations in PARK genes cause familial PD forms. Increased expression of alpha-synuclein (PARK4) is a disease-triggering event in familial PD and also observed in SN DA neurons in sporadic PD but related transcriptional changes are unknown. With optimized single-cell quantitative real-time polymerase chain reaction analysis, we compared messenger RNA and microRNA levels in SN DA neurons from sporadic PD patients and controls. Non-optimally matched donor ages and RNA integrities are common problems when analyzing human samples. We dissected the influence of distinct ages and RNA integrities of our samples by applying a specifically-optimized, linear-mixed-effects model to quantitative real-time polymerase chain reaction-data. We identified that elevated alpha-synuclein messenger RNA levels in SN DA neurons of human PD brains were positively correlated with corresponding elevated levels of mRNAs for functional compensation of progressive SN DA loss and for enhanced proteasomal (PARK5/UCHL1) and lysosomal (PARK9/ATPase13A2) function, possibly counteracting alpha-synuclein toxicity. In contrast, microRNA miR-133b levels, previously implicated in transcriptional dysregulation in PD, were not altered in SN DA neurons in PD. Elsevier 2014-10 /pmc/articles/PMC4099518/ /pubmed/24742361 http://dx.doi.org/10.1016/j.neurobiolaging.2014.03.016 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Regular Article
Schlaudraff, Falk
Gründemann, Jan
Fauler, Michael
Dragicevic, Elena
Hardy, John
Liss, Birgit
Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title_full Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title_fullStr Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title_full_unstemmed Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title_short Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease()
title_sort orchestrated increase of dopamine and park mrnas but not mir-133b in dopamine neurons in parkinson's disease()
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099518/
https://www.ncbi.nlm.nih.gov/pubmed/24742361
http://dx.doi.org/10.1016/j.neurobiolaging.2014.03.016
work_keys_str_mv AT schlaudrafffalk orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease
AT grundemannjan orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease
AT faulermichael orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease
AT dragicevicelena orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease
AT hardyjohn orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease
AT lissbirgit orchestratedincreaseofdopamineandparkmrnasbutnotmir133bindopamineneuronsinparkinsonsdisease